Pfizer Signals Waning Interest In Biosimilars

 
• By Jessica Merrill

Despite commercial success in biosimilars, Pfizer said it is more interested in investing in innovative therapeutics.

bored dog
Pfizer suggested it is losing interest in biosimilars • Source: Alamy

More from Strategy

More from Business